#1
#1 out of 2
health19m ago
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
- Biopharma players have heavily pursued PD-1/VEGF bispecifics, betting on their potential in cancer therapy.
- Ivonescimab showed a positive impact on disease progression in global trials, but the death-risk reduction was not statistically significant.
- Analyst Souro Chowdhury argues liver tumors and gastric cancers may better exploit the VEGF pathway.
- Lung cancer remains the main focus for several companies testing PD-1/VEGF bispecifics.
- Global trial readouts will determine if the approach can be generalized beyond lung cancer.
- BioNTech’s pumitamig targets VEGF and PD-L1 in multiple tumor types beyond lung cancer.
- Industry experts view the strategy as potentially derisking large acquisitions through broader indications.
- The article highlights the need for more diverse trial populations to validate results globally.
- The discussion encompasses broader trials outside lung cancer, including colorectal and liver cancer.
- The piece notes ongoing large phase 3 trials outside lung cancer as developers diversify.
- The article serves as a snapshot of the current bispecifics landscape and commentary from Lifescience Dynamics analysts.
Vote 0
